<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04441918</url>
  </required_header>
  <id_info>
    <org_study_id>JS016-001-I</org_study_id>
    <nct_id>NCT04441918</nct_id>
  </id_info>
  <brief_title>Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Study to Evaluate the Tolerability, Safety, Pharmacokinetic Profile and Immunogenicity of JS016 (Anti-SARS-CoV-2 Monoclonal Antibody) Injection in Chinese Healthy Subjects After Intravenous Infusion of Single Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Junshi Bioscience Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Junshi Bioscience Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled, phase I clinical study to evaluate&#xD;
      the tolerability, safety, pharmacokinetic profile and immunogenicity of JS016&#xD;
      (anti-SARS-CoV-2 monoclonal antibody) injection in Chinese healthy subjects after intravenous&#xD;
      infusion of single dose.Eligible patients will be injection JS016 (anti-SARS-CoV-2 monoclonal&#xD;
      antibody)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2020</start_date>
  <completion_date type="Anticipated">December 11, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of adverse events with the investigational product</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Any adverse event, serious adverse event (SAE) occurred during the clinical study, including clinical symptoms and abnormal vital signs, abnormal laboratory tests (complete blood cell count, serum chemistry, routine urinalysis, coagulation function, etc.) and 12-lead ECGs will be observed for all the subjects, the their clinical manifestations and features, severity, time to onset, end time, therapeutic measures and outcomes will be recorded, and the correlation of the adverse events with the investigational product will be judged</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary pharmacokinetic variables</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Area under the curve from the time of dosing to the last measurable concentration time t (AUC0-last);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary pharmacokinetic variables</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Maximum concentration (Cmax);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary pharmacokinetic variables</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Mean residence time (MRT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Primary pharmacokinetic variables</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Terminal half life (t1/2);</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pharmacokinetic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Area under the analyte concentration-time curve from time 0 and extrapolated to infinite time (AUC0-∞);</description>
  </other_outcome>
  <other_outcome>
    <measure>pharmacokinetic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Time to maximum concentration (Tmax);</description>
  </other_outcome>
  <other_outcome>
    <measure>pharmacokinetic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Clearance (CL);</description>
  </other_outcome>
  <other_outcome>
    <measure>pharmacokinetic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Apparent terminal elimination rate constant (λz)</description>
  </other_outcome>
  <other_outcome>
    <measure>pharmacokinetic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Apparent volume of distribution (Vd)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>COVID-19; and High Infection Risk of SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>JS016 (anti-SARS-CoV-2 monoclonal antibody)</intervention_name>
    <description>JS016 (anti-SARS-CoV-2 monoclonal antibody)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects aged 18 to 45 years, inclusive;&#xD;
&#xD;
          2. The body weight no less than 50 kg for male subjects and no less than 45 kg for female&#xD;
             subjects. Body mass index (BMI) = weight (kg)/square of height (m2), ranging from&#xD;
             18-28 kg/m2 (including the critical value);&#xD;
&#xD;
          3. Normal or abnormal but clinically insignificant physical examination, vital signs,&#xD;
             laboratory tests and other accessory examinations (chest radiology, abdominal B-mode&#xD;
             ultrasonography, ECG, etc.);&#xD;
&#xD;
          4. No plan of pregnancy and being willing to use effective contraceptive measures for&#xD;
             subject (including partner) from informed consent to 6 months after administration of&#xD;
             investigational product, see Appendix 5 for the specific contraceptive measures;&#xD;
&#xD;
          5. The subjects are able to understand the content of the study and voluntary to sign the&#xD;
             informed consent form; meanwhile, being able to complete the study as required in the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Excluded for novel coronavirus (SARS-CoV-2) infection&#xD;
&#xD;
          1. Having one of the following evidence on SARS-CoV-2 infection:&#xD;
&#xD;
               1. SARS-CoV-2 determined by reverse transcription-polymerase chain reaction (RT-PCR)&#xD;
                  and/or next generation sequencing (NGS) in diagnostic specimens (nasopharyngeal&#xD;
                  swabs) during screening and pre-randomization (results within 3 days before&#xD;
                  randomization are accepted);&#xD;
&#xD;
               2. Previous viral gene sequencing showed high homology with the known SARS-CoV-2;&#xD;
&#xD;
               3. Positive specific antibody IgM or IgG against serum SARS-CoV-2; Excluded for&#xD;
                  previous and concomitant medications&#xD;
&#xD;
          2. Previous vaccination of SARS-CoV-2 vaccine or having participated in the clinical&#xD;
             trial on SARS-CoV-2 neutralizing antibody;&#xD;
&#xD;
          3. Use of therapeutic biologics within 12 weeks prior to screening, or remaining in the&#xD;
             elimination period of the drug (within 5 half-lives) at random administration,&#xD;
             whichever is longer;&#xD;
&#xD;
          4. Participation in any other clinical study with intervention of investigational product&#xD;
             within 4 weeks prior to screening, or remaining in the elimination period of the drug&#xD;
             (within 5 half-lives) prior to screening, whichever is longer;&#xD;
&#xD;
          5. Vaccination of vaccine within 12 weeks prior to screening, or plan to use Bacille&#xD;
             Calmette-Guérin vaccine or other vaccine during the study and within 12 weeks after&#xD;
             the study;&#xD;
&#xD;
          6. Use of hydroxychloroquine, herbal medicine, any prescription drug or over-the-counter&#xD;
             drug within (inclusive) 14 days prior to screening; Surgery&#xD;
&#xD;
          7. Any major surgery within 8 weeks (inclusive) prior to screening, or requiring such&#xD;
             surgery during the study, and such surgery is considered by the investigator to&#xD;
             possibly bring unacceptable risk for subjects upon confirmation with the sponsor;&#xD;
             Abnormal physical examination, laboratory examination and history&#xD;
&#xD;
          8. Lying systolic blood pressure (SBP) &gt; 140 mmHg or &lt; 90 mmHg, and/or diastolic blood&#xD;
             pressure (DBP) &gt; 90 mmHg or &lt; 50 mmHg at screening and randomization;&#xD;
&#xD;
          9. Total white blood cell (WBC) count &lt; 3.5 x 109/L, platelet &lt; 140 x 109/L, neutrophil &lt;&#xD;
             2.0 x 109/L, or hemoglobin decreased (male &lt; 135 g/L, female &lt; 120 g/L), lymphocytes &lt;&#xD;
             1.0 x 109/L at screening;&#xD;
&#xD;
         10. ALT or AST &gt; 2 × upper limit of normal, or eGFR ≤ 90 mL/min/1.73m2 at screening;&#xD;
&#xD;
         11. Abnormal ECG at screening, single QTcF &gt; 450 msec, and/or other abnormalities of&#xD;
             clinical significance, unacceptable risk that may be brought by participation in the&#xD;
             study;&#xD;
&#xD;
         12. History of HIV infection, and/or positive aiti-HIV antibody, positive hepatitis B&#xD;
             surface antigen (HBsAg), positive hepatitis C antibody (anti-HCV), or&#xD;
             positivetreponema pallidum particle agglutination test (TPPA) at screening;&#xD;
&#xD;
         13. History of transplantation of vital organs (e.g., heart, lung, liver, kidney, etc.);&#xD;
&#xD;
         14. Having malignant tumor (excluding the malignant tumor cured with no recurrence in the&#xD;
             past 5 years, completely resected basal cell and squamous cell carcinoma of skin,&#xD;
             completely resected carcinoma in situ of any type);&#xD;
&#xD;
         15. Other major diseases within one year;&#xD;
&#xD;
         16. Medical history and previous history suggest the following diseases: including but not&#xD;
             limited to gastrointestinal, renal, hepatic, neurological, hematological, endocrine,&#xD;
             oncological, pulmonary, immune, mental or cerebro- and cardiovascular diseases;&#xD;
             Substance abuse, alcohol abuse&#xD;
&#xD;
         17. History of drug abuse or use of narcotics in the past 5 years, or positive urine drug&#xD;
             screening;&#xD;
&#xD;
         18. History of alcohol abuse or intake of excessive alcohol in the past 6 months (14 units&#xD;
             of alcohol per week: 1 unit = 285 mL beer, or 25 mL liquor, or 100 mL wine), or&#xD;
             alcohol test positive; History of allergies&#xD;
&#xD;
         19. Known serious allergic reaction or hypersensitive to food, inhaled and contact&#xD;
             material as well as drugs, or allergic constitution (allergy to various drugs and&#xD;
             food);&#xD;
&#xD;
         20. Known history of allergy or hypersensitivity to the investigational drug, other&#xD;
             monoclonal antibody drugs and therapeutic protein preparations (fresh or frozen&#xD;
             plasma, human serum albumin, cytokine, interleukin etc.); Pregnancy, lactation&#xD;
&#xD;
         21. Positive β-Human Chorionic Gonadotropin (β-HCG) or breastfeeding female subjects;&#xD;
             Blood loss and others&#xD;
&#xD;
         22. Subjects who lost blood or donated more than 400 mL, or received blood transfusion in&#xD;
             the past 3 months; or plan to donate blood during the study;&#xD;
&#xD;
         23. Any other condition that the subject is considered by the investigator as&#xD;
             inappropriate to participate in the study, for example, potential compliance issue,&#xD;
             inability to complete all the tests and evaluations according to the requirements in&#xD;
             the protocol, or uncontrolled mental, neurological or psychological disorders,&#xD;
             participation in the study is judged by the investigator to be associated with&#xD;
             uncontrollable risk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jing Zhang</last_name>
    <phone>021-52888189</phone>
    <email>13816357098@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenhong Zhang</last_name>
    <phone>021-52888123</phone>
    <email>zhangwenhong@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Huashan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Zhang</last_name>
      <phone>02152888189</phone>
      <phone_ext>02152888189</phone_ext>
      <email>13816357098@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenhong Zhang</last_name>
      <phone>02152888123</phone>
      <phone_ext>02152888123</phone_ext>
      <email>zhangwenhong@fudan.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 6, 2020</study_first_submitted>
  <study_first_submitted_qc>June 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 22, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

